Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy
Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer. It is metabolized into fluorouracil (5-FU) in the liver; hence, its mechanism of action is similar to that of 5-FU. Cardiac toxicity, although rarely seen, may be of concern in som...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KARE Publishing
2016-02-01
|
| Series: | Türk Kardiyoloji Derneği Arşivi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-36005 |
| _version_ | 1828026516667105280 |
|---|---|
| author | Uğur Nadir Karakulak Elifcan Aladağ Naresh Maharjan Kenan Övünç |
| author_facet | Uğur Nadir Karakulak Elifcan Aladağ Naresh Maharjan Kenan Övünç |
| author_sort | Uğur Nadir Karakulak |
| collection | DOAJ |
| description | Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer. It is metabolized into fluorouracil (5-FU) in the liver; hence, its mechanism of action is similar to that of 5-FU. Cardiac toxicity, although rarely seen, may be of concern in some patients. Although multiple hypotheses have been proposed for the mechanism of cardiotoxicity, coronary vasospasm is the most commonly accepted one, as patients usually present with chest pain resembling acute myocardial infarction. Electrocardiography may demonstrate ST-segment elevation, and cardiac biomarkers may be elevated. Cardiotoxicity with 5-FU has been reported widely. Capecitabine has been shown to be much less cardiotoxic compared to 5-FU, with only a handful of cases reporting cardiotoxicity with capecitabine. There are no cases reporting cardiotoxicity with both 5-FU and capecitabine in the same patient. In this case report, we present a patient with adverse cardiac effect with capecitabine whose previous 5-FU therapy was stopped due to cardiotoxicity. |
| first_indexed | 2024-04-10T13:20:36Z |
| format | Article |
| id | doaj.art-bc3a1ef0ebcd43cc915bbf7503d62514 |
| institution | Directory Open Access Journal |
| issn | 1016-5169 |
| language | English |
| last_indexed | 2024-04-10T13:20:36Z |
| publishDate | 2016-02-01 |
| publisher | KARE Publishing |
| record_format | Article |
| series | Türk Kardiyoloji Derneği Arşivi |
| spelling | doaj.art-bc3a1ef0ebcd43cc915bbf7503d625142023-02-15T16:12:05ZengKARE PublishingTürk Kardiyoloji Derneği Arşivi1016-51692016-02-01441717410.5543/tkda.2015.36005TKDA-36005Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapyUğur Nadir Karakulak0Elifcan Aladağ1Naresh Maharjan2Kenan Övünç3Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Internal Medicine, Division of Oncology, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, TurkeyCapecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer. It is metabolized into fluorouracil (5-FU) in the liver; hence, its mechanism of action is similar to that of 5-FU. Cardiac toxicity, although rarely seen, may be of concern in some patients. Although multiple hypotheses have been proposed for the mechanism of cardiotoxicity, coronary vasospasm is the most commonly accepted one, as patients usually present with chest pain resembling acute myocardial infarction. Electrocardiography may demonstrate ST-segment elevation, and cardiac biomarkers may be elevated. Cardiotoxicity with 5-FU has been reported widely. Capecitabine has been shown to be much less cardiotoxic compared to 5-FU, with only a handful of cases reporting cardiotoxicity with capecitabine. There are no cases reporting cardiotoxicity with both 5-FU and capecitabine in the same patient. In this case report, we present a patient with adverse cardiac effect with capecitabine whose previous 5-FU therapy was stopped due to cardiotoxicity.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-36005capecitabinecardiac toxicity; coronary vasospasm. |
| spellingShingle | Uğur Nadir Karakulak Elifcan Aladağ Naresh Maharjan Kenan Övünç Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy Türk Kardiyoloji Derneği Arşivi capecitabine cardiac toxicity; coronary vasospasm. |
| title | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| title_full | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| title_fullStr | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| title_full_unstemmed | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| title_short | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| title_sort | capecitabine induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy |
| topic | capecitabine cardiac toxicity; coronary vasospasm. |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-36005 |
| work_keys_str_mv | AT ugurnadirkarakulak capecitabineinducedcoronaryarteryvasospasminapatientwhopreviouslyexperiencedasimilarepisodewithfluorouraciltherapy AT elifcanaladag capecitabineinducedcoronaryarteryvasospasminapatientwhopreviouslyexperiencedasimilarepisodewithfluorouraciltherapy AT nareshmaharjan capecitabineinducedcoronaryarteryvasospasminapatientwhopreviouslyexperiencedasimilarepisodewithfluorouraciltherapy AT kenanovunc capecitabineinducedcoronaryarteryvasospasminapatientwhopreviouslyexperiencedasimilarepisodewithfluorouraciltherapy |